FineLine Technologies has acquired Digi-Trax, a leading provider of healthcare labeling and identification solutions that support safety, traceability and compliance in the blood and cell-therapy supply network. Digi-Trax will operate as FineLine’s new Healthcare Division.
Digi-Trax software and hardware solutions meet ISBT-128 international standards for coding and labeling medical products of human origin, such as blood, tissues and cell samples. Its solutions integrate with multiple health IT platforms and laboratory information systems. Digi-Trax offers barcoding hardware, software, supplies and support, including both bundled and stand-alone offerings such as HemaTrax ISBT compliant labeling system, HemaTrax-CT on-demand print solution for ISBT 128 cellular therapy labeling, and RepliTrax standalone bar-code label replication system.
“We look forward to leveraging Digi-Trax’s expertise to drive growth and expand our presence in the global healthcare sector,” said George Hoffman, CEO of FineLine Technologies. “Digi-Trax has an outstanding 40-year legacy of customer service and continuous innovation. Together we will offer customers an all-in-one labeling solution – from barcode hardware and supplies to software.”
FineLine offers a global RFID tag, label and packaging portfolio, with the largest U.S. printing and encoding capacity. Its service bureau network manages the entire fulfillment process – from data processing and quality control to packaging and distribution.
“We’re excited about this next phase for Digi-Trax. Operating as a FineLine company, Digi-Trax will leverage FineLine’s scale, robust global infrastructure and large vendor network,” said Jeff Kriozere, Digi-Trax owner and son of the company’s founder. “FineLine is the perfect partner to help us further enable hospitals, blood centers and cell therapy facilities to maintain regulatory compliance while improving operational efficiency. Our team remains dedicated to providing the same outstanding products, service and support that our customers have come to expect. This transition allows us to build on our legacy while continuing to innovate for the future. I look forward to remaining with the company and continuing to lead the organization into its next chapter.”
